<!DOCTYPE html><html lang="en-us" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.8.0">

  

  
  
  
  
  
  

  

  
  
  
    
  
  <meta name="description" content="ALK receptor tyrosine kinase
Gene Context Sentence Table 2. Analysis of context sentence of ALK gene in 15 abstracts.   PMID  Gene Context Sentence      23856136  Clinical and pathological data were collected, including age, gender, smoking status, treatment, response, and molecular biomarkers such as thymidylate synthetase (TS) expression, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) gene rearrangement.">

  
  <link rel="alternate" hreflang="en-us" href="/mesothelioma/genepanel/238/gene_context/">

  


  
  
  
  <meta name="theme-color" content="#2962ff">
  

  
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.0-1/css/all.min.css" integrity="sha256-4w9DunooKSr3MFXHXWyFER38WmPdm361bQS/2KUWZbU=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/github.min.css" crossorigin="anonymous" title="hl-light">
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark" disabled>
        
      
    

    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js" integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    

  

  
  
  
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
  

  
  
  
  
  <link rel="stylesheet" href="/mesothelioma/css/academic.css">

  





<script async src="https://www.googletagmanager.com/gtag/js?id=google_analytics_ID"></script>
<script>
  window.dataLayer = window.dataLayer || [];

  function gtag() {
      dataLayer.push(arguments);
  }

  function trackOutboundLink(url, target) {
    gtag('event', 'click', {
         'event_category': 'outbound',
         'event_label': url,
         'transport_type': 'beacon',
         'event_callback': function () {
           if (target !== '_blank') {
             document.location = url;
           }
         }
    });
    console.debug("Outbound link clicked: " + url);
  }

  function onClickCallback(event) {
    if ((event.target.tagName !== 'A') || (event.target.host === window.location.host)) {
      return;
    }
    trackOutboundLink(event.target, event.target.getAttribute('target'));  
  }

  gtag('js', new Date());
  gtag('config', 'google_analytics_ID', {});

  
  document.addEventListener('click', onClickCallback, false);
</script>


  


  
  

  

  <link rel="manifest" href="/mesothelioma/index.webmanifest">
  <link rel="icon" type="image/png" href="/mesothelioma/images/icon_hu3365e08ad5ef6cb6d886bc511b9ad2b3_313689_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/mesothelioma/images/icon_hu3365e08ad5ef6cb6d886bc511b9ad2b3_313689_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="/mesothelioma/genepanel/238/gene_context/">

  
  
  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="mesothelioma">
  <meta property="og:url" content="/mesothelioma/genepanel/238/gene_context/">
  <meta property="og:title" content="ALK | mesothelioma">
  <meta property="og:description" content="ALK receptor tyrosine kinase
Gene Context Sentence Table 2. Analysis of context sentence of ALK gene in 15 abstracts.   PMID  Gene Context Sentence      23856136  Clinical and pathological data were collected, including age, gender, smoking status, treatment, response, and molecular biomarkers such as thymidylate synthetase (TS) expression, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) gene rearrangement."><meta property="og:image" content="/mesothelioma/images/icon_hu3365e08ad5ef6cb6d886bc511b9ad2b3_313689_512x512_fill_lanczos_center_2.png">
  <meta property="twitter:image" content="/mesothelioma/images/icon_hu3365e08ad5ef6cb6d886bc511b9ad2b3_313689_512x512_fill_lanczos_center_2.png"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2019-05-05T00:00:00&#43;01:00">
    
    <meta property="article:modified_time" content="2019-05-05T00:00:00&#43;01:00">
  

  



  


  


  





  <title>ALK | mesothelioma</title>

</head>

<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" >

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  







<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/mesothelioma/">mesothelioma</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/mesothelioma/">mesothelioma</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/syntax/"><span>Syntax</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link  active" href="/mesothelioma/genepanel/"><span>Gene Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/drugpanel/"><span>Drug Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/tissuepanel/"><span>Tissue Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/syntax_summary/"><span>Literature Consensus</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/#about"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      

      

    </ul>

  </div>
</nav>


  

<div class="container-fluid docs">
  <div class="row flex-xl-nowrap">
    <div class="col-12 col-md-3 col-xl-2 docs-sidebar">
      





  
    
  




<form class="docs-search d-flex align-items-center">
  <button class="btn docs-toggle d-md-none p-0 mr-3" type="button" data-toggle="collapse" data-target="#docs-nav" aria-controls="docs-nav" aria-expanded="false" aria-label="Toggle section navigation">
    <span><i class="fas fa-bars"></i></span>
  </button>

  
  <input name="q" type="search" class="form-control" placeholder="Search..." autocomplete="off">
  
</form>

<nav class="collapse docs-links" id="docs-nav">
  

  
  
  
  
  <div class="docs-toc-item">
    <a class="docs-toc-link" href="/mesothelioma/genepanel/238/info/">Overview</a>
    <ul class="nav docs-sidenav">
      
      <li >
        <a href="/mesothelioma/genepanel/238/gene_expression/">Gene Expression</a>
      </li>
      
      <li class="active">
        <a href="/mesothelioma/genepanel/238/gene_context/">Gene Context</a>
      </li>
      
      <li >
        <a href="/mesothelioma/genepanel/238/clinvar/">ClinVar</a>
      </li>
      
      <li >
        <a href="/mesothelioma/genepanel/238/geo/">Geo DataSet</a>
      </li>
      
    </ul>
    

  </div>
  
  
</nav>

    </div>

    

    <main class="col-12 col-md-9 col-xl-8 py-md-3 pl-md-5 docs-content" role="main">

      <article class="article">

        <div class="docs-article-container">
          <h1>ALK</h1>

          <div class="article-style">
            
<script src="/mesotheliomarmarkdown-libs/kePrint/kePrint.js"></script>


<hr />
<p>ALK receptor tyrosine kinase</p>
<hr />
<div id="gene-context-sentence" class="section level2">
<h2>Gene Context Sentence</h2>
<br>
<p style="font-size:12px" align="center">
<strong>Table 2.</strong> Analysis of context sentence of ALK gene in 15 abstracts.
</p>
<table class="table table-striped" style="width: auto !important; margin-left: auto; margin-right: auto;">
<thead>
<tr>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
PMID
</th>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
Gene Context Sentence
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:center;">
<a href="/publication/23856136" target="_blank">23856136</a>
</td>
<td style="text-align:center;">
Clinical and pathological data were collected, including age, gender, smoking status, treatment, response, and molecular biomarkers such as thymidylate synthetase (TS) expression, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) gene rearrangement. […] Fluorescence in situ hybridization (FISH) was performed to detect EML4-ALK gene rearrangement. […] EML4-ALK gene rearrangement was studied in 32 patients and 6 (18.8%) were positive. […] The MST was 19.6 months (95% CI: 6.0 - 7.9) in EML4-ALK-positive patients and 9.57 months (95% CI: 2.7 - 4.3) in negative ones (P = 0.159). […] Correlation between TS expression or EML4-ALK rearrangement and outcome of pemetrexed-based chemotherapy for MPM may contribute to future individualized treatment, which needs further validation from large-scale prospective studies.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/25653542" target="_blank">25653542</a>
</td>
<td style="text-align:center;">
Lung adenocarcinoma is the predominant subtype and there is increasing knowledge on therapeutic molecular targets, namely EGFR, ALK, KRAS, and ROS1, among lung cancers. […] Lung cancer cell lines established with known clinical characteristics and molecular profiling of oncogenic targets like ALK or KRAS could be useful tools for understanding the biology of known molecular targets as well as for drug testing and screening. […] They were characterized by immunohistochemistry, growth kinetics, tests for tumorigenicity, EGFR and KRAS gene mutations, ALK gene rearrangement and OncoSeq mutation profiling. […] One of these new cell lines bears EML4-ALK rearrangement variant 2, two lung cancer cell lines bear different KRAS mutations at codon 12, and known single nucleotide polymorphism variants were identified in these cell lines.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/27623107" target="_blank">27623107</a>
</td>
<td style="text-align:center;">
Here, we studied the combinatorial therapeutic efficacy of the MET/ALK inhibitor crizotinib, with either a pan-class I PI3K inhibitor, BKM120, or with a PI3K/mTOR dual inhibitor, GDC-0980, in mesothelioma.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/28910456" target="_blank">28910456</a>
</td>
<td style="text-align:center;">
To investigate anaplastic lymphoma kinase (ALK) rearrangements in a large series of peritoneal mesothelioma and characterize the mutational landscape of these tumors. […] We identified ALK-positive mesotheliomas by immunohistochemistry and confirmed ALK rearrangement by fluorescence in situ hybridization (FISH). […] In ALK-rearranged cases, we characterized the fusion partners using targeted next-generation sequencing of both tumor DNA and RNA. […] We also explored ALK rearrangement in a separate series of 205 patients with pleural mesothelioma. […] Identification and characterization of novel ALK rearrangements and correlations with clinicopathologic characteristics. […] In focal weak ALK-positive cases, no ALK rearrangement was detected by FISH or next-generation sequencing. […] In strong diffuse ALK-positive cases, FISH confirmed ALK rearrangements, and next-generation sequencing identified novel fusion partners ATG16L1, STRN, and TPM1. […] Patients with ALK-rearranged peritoneal mesotheliomas were women and younger than patients without ALK rearrangement (median age 36 vs 62; Mann-Whitney test, P = .02), but all other clinicopathologic characteristics (size of tumor nodules, histology, treatment, and survival) were not different. […] No asbestos fibers were detected in ALK-rearranged cases. […] Furthermore, loss of chromosomal region 9p or 22q or genetic alterations in BAP1, SETD2, or NF2 typically present in peritoneal mesothelioma were absent in the ALK-rearranged cases. […] All pleural mesotheliomas were ALK-negative by immunohistochemistry. […] We identified unique ALK rearrangements in a subset of patients with peritoneal mesothelioma, each lacking asbestos fibers, therapeutic radiation, and cytogenetic and molecular alterations typically found in these tumors. […] Identification of clinically actionable ALK rearrangements may represent a novel pathogenetic mechanism of malignant peritoneal mesothelioma with promise for targeted therapy.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/29755689" target="_blank">29755689</a>
</td>
<td style="text-align:center;">
Here, we examined ALK, MET and mTOR as potential therapeutic targets and determined the combinatorial efficacy of ALK and mTOR targeting on tumor cell growth <i>in vivo</i>. […] First, <i>ALK</i> overexpression, rearrangement and mutation were studied in primary MPM by qRT-PCR, FISH, immunohistochemistry and sequence analysis; <i>mTOR</i> and <i>MET</i> expression by qRT-PCR and immunohistochemistry. […] Overexpression of full-length <i>ALK</i> transcripts was observed in 25 (19.5%) of 128 primary MPM, of which ten expressed ALK protein. <i>ALK</i> overexpression was not associated with gene rearrangement, amplification or kinase-domain mutation. mTOR protein was detected in 28.7% MPM, co-expressed with ALK or MET in 5% and 15% MPM, respectively. […] The ALK/MET inhibitor crizotinib enhanced the anti-tumor effect of the mTOR-inhibitor rapamycin in a patient-derived MPM xenograft with co-activated ALK/mTOR: combined therapy achieved tumor shrinkage in 4/5 tumors and growth stagnation in one tumor. […] Rapamycin/crizotinib simultaneously inhibited mTORC1 (evidenced by S6 kinase and RPS6 dephosphorylation) and ALK signaling (ALK, AKT, STAT3 dephosphorylation), and crizotinib suppressed the adverse AKT activation induced by rapamycin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/30246568" target="_blank">30246568</a>
</td>
<td style="text-align:center;">
In advanced non-small cell lung cancer, molecular targeted therapy is the standard first-line treatment for patients with identified driver mutations; on the other hand, chemotherapy is the standard treatment for patients without EGFR mutations or ALK rearrangement or those with unknown mutation status.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/30450291" target="_blank">30450291</a>
</td>
<td style="text-align:center;">
An exciting finding was the demonstration of ALK rearrangements in a small subset of patients with MPM and it is hoped for that at least this small subgroup of patients could benefit from treatment with ALK inhibitors.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/30595194" target="_blank">30595194</a>
</td>
<td style="text-align:center;">
In France, approvals have been pronounced for nivolumab and pembrolizumab (anti-PD-1 antibodies) as second-line treatments after chemotherapy in patients with advanced NSCLC, and pembrolizumab has been approved as a first-line treatment in patients with advanced NSCLC, without EGFR mutation or ALK rearrangement, with strong (≥50%) PD-L1 (Programmed Death Ligand 1) expression.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/31443309" target="_blank">31443309</a>
</td>
<td style="text-align:center;">
Additionally, the process of pathogenesis is greatly affected by activating mutations of <i>EGFR</i>, <i>KRAS</i>, <i>PIK3CA</i>, <i>BRAF</i>, <i>MET</i>, <i>EML4/ALK</i> and <i>RET</i>, which correlate with an increased incidence of MPE.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/31661685" target="_blank">31661685</a>
</td>
<td style="text-align:center;">
A case of peritoneal mesothelioma with an anaplastic lymphoma kinase (ALK) translocation was identified, and we conducted further studies to obtain diagnostic and therapeutic insights. […] Surprisingly, the tumor was ALK-positive, and ALK recombination was confirmed by an ALK break-apart test. […] Retrospectively, cells and tissue specimens were stained with ALK intercalated antibody-enhanced polymer. […] Recombination in ALK was reconfirmed by the National Cancer Center Japan, and the patient was enrolled in a clinical trial for alectinib.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/31783178" target="_blank">31783178</a>
</td>
<td style="text-align:center;">
In this study, we evaluated for the presence of the anaplastic lymphoma kinase (ALK) translocations in these patients. […] In a prospective study of mesothelioma natural history (ClinicalTrials.gov number NCT01950572), we assessed for the presence of the ALK translocation in patients younger than 40 years, irrespective of the site of disease. […] If the patients tested positive for the ALK translocation, both immunohistochemistry and RNA sequencing were performed on the tumor specimen. […] Presence of an ALK translocation by FISH was seen in two of the 32 patients (6%) with mesothelioma. […] Neither had detectable ALK expression by immunohistochemistry. […] Young patients with peritoneal mesothelioma should be evaluated for the presence of ALK translocations. […] Presence of this translocation should be assessed by FISH and these patients could potentially benefit from tyrosine kinase inhibitors targeting ALK.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32088605" target="_blank">32088605</a>
</td>
<td style="text-align:center;">
Samples from both the primary tumor and the metastasis were molecularly characterized, the pleural sample proving ALK-positive and the brain sample, ALK-negative.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32181989" target="_blank">32181989</a>
</td>
<td style="text-align:center;">
It has been proven that ALK-rearranged non-small cell lung cancer (NSCLC) is sensitive to ALK inhibitors while the chemotherapy resistance is unavoidable. […] In this study, safety and antitumor activity of the novel ALK inhibitor (ALKi) CT-707 were evaluated in Chinese patients with advanced ALK-rearranged NSCLC. […] This single-center, open-label phase I study recruited adult patients with ALK-rearrangement (confirmed by fluorescence in situ hybridization and/or immunohistochemistry) of locally advanced/metastatic malignancies including NSCLC. […] This study indicated that CT-707 is clinically effective as a new antitumor drug for Chinese lung adenocarcinoma patients with ALK rearrangement.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32540558" target="_blank">32540558</a>
</td>
<td style="text-align:center;">
Gene rearrangements involving NTRK1, NTRK2, NTRK3, ROS1 and ALK have been identified in many types of cancer, including non-small cell lung cancer (NSCLC). […] Given the activity of NTRK, ROS-1 and ALK inhibitors in tumors harboring gene fusions, we sought to explore such rearrangements in these less common tumors in addition to NSCLC. […] Immunohistochemistry (IHC) was performed using a cocktail of antibodies against TRK, ROS1 and ALK. […] The following fusions were detected: one MPM with an NTRK ex10-TPM3 ex8, another MPM with an ALK ex20-EML4ex13, one lung intermediate-grade NET (atypical carcinoid) with an ALK ex20-EML4 ex6/intron6, and two NSCLCs with an ALK ex20-EML4 ex6/intron6 rearrangement. […] To our knowledge, we report for the first time NTRK and ALK rearrangements in a small subset of MPM. […] An ALK rearrangement was also detected in lung intermediate-grade NET (or atypical carcinoid).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32600123" target="_blank">32600123</a>
</td>
<td style="text-align:center;">
<i>EML4-ALK</i> rearranged malignant pleural mesothelioma (MPM) is rare and its responses to anaplastic lymphoma kinase (ALK) inhibitors, including alectinib and lorlatinib, remain unexplored. […] In this case report, we describe a patient with <i>EML4-ALK</i>-rearranged stage IIIB MPM who was administered with alectinib and lorlatinib as first-line and fourth-line therapy, respectively. […] Sequencing analysis revealed the emergence of <i>ALK</i> I1171N and L1196M at alectinib progression. […] Meanwhile, <i>ALK</i> I1171N, L1196M, and G1202R mutations were identified at lorlatinib progression, wherein L1196M is confirmed to be in <i>cis</i> to G1202R. […] Our report describes the detection of <i>EML4-ALK</i> rearrangement in a patient with MPM who had remarkable therapeutic response with ALK inhibitors. […] Moreover, our case also revealed acquired mechanisms of lorlatinib resistance mediated by multiple mutations <i>ALK</i> I1171N, L1196M, and G1202R, contributing an incremental step to our understanding of the complexity of acquired resistance mechanisms in sequential ALK inhibitor therapy. <i>The reviews of this paper are available via the supplemental material section.</i>
</td>
</tr>
</tbody>
</table>
<hr />
</div>

          </div>

          



          
        </div>

        <div class="body-footer">
          
          

          
        </div>

      </article>

      <footer class="site-footer">
  
  <p class="powered-by">
    
      <a href="/mesothelioma/privacy/">Privacy Policy</a>
    
    
        &middot; 
      <a href="/mesothelioma/terms/">Terms</a>
    
    
        &middot; 
      <a href="/mesothelioma/supp/faq/">FAQ</a>
    
  </p>
  

  <p class="powered-by">
    BioHub - UFPE &middot; 

    Powered by the
    <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
    <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

    
  </p>
</footer>


    </main>
  </div>
</div>


      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>

      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/highlight.min.js" integrity="sha256-eOgo0OtLL4cdq7RdwRUiGKLX9XsIJ7nGhWEKbohmVAQ=" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/languages/r.min.js"></script>
        
      

    

    
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    <script>const isSiteThemeDark = false;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/mesothelioma/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks"
        };
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/anchor-js/4.1.1/anchor.min.js" integrity="sha256-pB/deHc9CGfFpJRjC43imB29Rse8tak+5eXqntO94ck=" crossorigin="anonymous"></script>
    <script>
      anchors.add();
    </script>
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    

    
    
    <script id="dsq-count-scr" src="https://procovid19.disqus.com/count.js" async></script>
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/mesothelioma/js/academic.min.37431be2d92d7fb0160054761ab79602.js"></script>

    






  
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
